Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
5-Year IF – 2.0, IF – 1.9, JCI (2024) – 0.43
Scopus CiteScore – 4.3
Q1 in SJR 2024, SJR score – 0.598, H-index: 49 (SJR)
ICV – 161.00; MNiSW – 70 pts
Initial editorial assessment and first decision within 24 h

ISSN 1899–5276 (print), ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2010, vol. 19, nr 2, March-April, p. 143–150

Publication type: editorial article

Language: English

Anti-Tumor Necrosis Factor Alpha Antibodies for Remission Maintenance Therapy in Inflammatory Bowel Disease

Przeciwciała przeciwko czynnikowi martwicy nowotworów α w terapii podtrzymującej remisję w nieswoistych zapaleniach jelit

Katarzyna Neubauer1,, Radosław Kempiński1,, Elżbieta Poniewierka1,

1 Department of Gastroenterology and Hepatology, Wroclaw Medical University, Poland

Abstract

Inflammatory bowel disease (IBD) comprises chronic inflammatory conditions of the digestive tract including ulcerative colitis, Crohn’s disease, and indeterminate colitis. The etiopathogenesis of IBD remains unknown and is probably multifactorial. A key pro-inflammatory cytokine in IBD is tumor necrosis factor α (TNF-α). The goals of the medical treatment of IBD include inducing a clinical response, maintaining clinical remission, mucosal healing, minimizing the use of corticosteroids, improvement of quality of life, and prevention of colorectal cancer. A huge advance in the therapy of inflammatory bowel disease has been the introduction of biological therapies with antiTNF-α antibodies (infliximab, adalimumab, certolizumab) already administrated in clinical practice.

Streszczenie

Nieswoiste zapalenia jelit to przewlekłe choroby przewodu pokarmowego obejmujące wrzodziejące zapalenie jelita grubego, chorobę Leśniowskiego-Crohna i nieokreślone zapalenie jelita grubego. Etiopatogeneza tych chorób pozostaje nieznana i przyjmuje się, że jest wieloczynnikowa. Kluczową cytokiną prozapalną w nieswoistych zapaleniach jelit jest czynnik martwicy nowotworów α (TNF-α). Wśród celów leczenia zachowawczego w nieswoistych zapaleniach jelit są: osiągnięcie odpowiedzi klinicznej (leczenie indukcyjne), podtrzymanie remisji, gojenie błony śluzowej, ograniczenie stosowania glukokortykosteroidów, poprawa jakości życia chorych, prewencja raka jelita grubego. Przełomem w terapii nieswoistych zapaleń jelit stało się wprowadzenie leków biologicznych, z których w praktyce klinicznej stosuje się przeciwciała anty-TNF-α (infliksymab, adalimumab, certolizumab).

Key words

inflammatory bowel disease, ulcerative colitis, Crohn’s disease, biological therapy, tumor necrosis factor α, infliximab, adalimumab, certolizumab

Słowa kluczowe

nieswoiste zapalenia jelit, wrzodziejące zapalenie jelita grubego, choroba Crohna, terapia biologiczna, czynnik martwicy nowotworów α, infliksymab, adalimumab, certolizumab

References (35)

  1. Paradowski L, Neubauer K, Kollbek P: Epidemiologia nieswoistych zapaleń jelit, skala problemu. Med Dypl 2007, Supl. 05/07, 33–37.
  2. Lakatos PL, Lakatos L: Risk for colorectal cancer in ulcerative colitis: changes, causes and management strategies. World J Gastroenterol 2009,14, 3937–3947.
  3. Sanchez-Munoz F, Dominguez-Lopez A, Yamamoto-Furusho JK: Role of cytokines in inflammatory bowel disease. World J Gastroenterol 2008, 14, 4280–4288.
  4. Murch SA, Braegger CP, Walker-Smith JA, MacDonald TT: Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease. Gut 1993, 34, 1705–1709.
  5. Braegger CP, Nicholls S, Murch SH, Stephens S, MacDonald TT: Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet 1992, 339, 89–91.
  6. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Rutgeerts P, ACCENT I Study Group: Maintenance infliximab for Crohn’s disease: the ACCENT I randomized trial. Lancet 2002, 359, 1541–1549.
  7. Rutgeerts P, Diamond RH, Bala M, Olson A, Lichtenstein GR, Bao W, Patel K, Wolf DC, Safdi M, Colombel JF, Lashner B, Hanauer SB: Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn’s disease. Gastrointest Endosc 2006, 63, 433–442.
  8. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJS, Present D, Sands BE, Colombel J-F: Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005, 353, 2462–2476.
  9. Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, Panaccione R, Wolf D, Pollack P: Human anti-tumor necrosis factor antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology 2006, 130, 323–333.
  10. Sandborn WJ, Hanauer SB, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh DG, Panaccione R, Wolf D, Kent JD, Bittle B, Li J, Pollack PF: Adalimumab for maintenance treatment of Crohn’s therapy: results of the CLASSIC II trial. Gut 2007, 56, 1232–1239.
  11. Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, Schreiber S, Byczkowski D, Li J, Kent JD, Pollack PF: Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology 2007, 132, 52–65.
  12. Panaccione R, Colombel J-F, Sandborn WJ, Rutgeerts P, D`Haens GR, Lomax KG, Li J, Pollack PF: Adalimumab maintains long-term remission in moderately to severely active Crohn’s disease through 3 years of therapy. Poster 148, presented at the Fourth Congress of the European Crohn’s Colitis Organisation 2009.
  13. Kamm MA, Hanauer SB, Panaccione R, Colombel J-F, Sandborn WJ, Lomax KG, Pollack PF: Steroid-free remission in patients with Crohn’s disease who received adalimumab therapy for at least 3 years: long-term results from CHARM. Poster 83 presented at the Fourth Congress of the European Crohn’s Colitis Organisation 2009.
  14. Feagan BG, Panaccione R, Sandborn WJ, D`Haens GR, Schreiber S, Rutgeerts PJ, Loftus Jr EV, Lomax KG, Yu AP, Wu EQ, Chao J, Mulani P: Effect of adalimumab therapy on incidence of hospitalization and surgery of Crohn’s disease: results from the CHARM study. Gastroenterology 2008, 135, 1493–1499.
  15. Loftus Jr EV, Feagan B, Chen N, Mulani P, Chao J: Risk of Crohn’s disease related hospitalization in patients receiving long-term adalimumab therapy: 3 year data from CHARM and ADHERE. Poster 33 presented at the Fourth Congress of the European Crohn’s Colitis Organisation 2009.
  16. Loftus Jr EV, Colombel J-F, Panaccione R, Rubin DT, Chen N, Chao J, Mulani P: Adalimumab sustains quality of life improvements in patients with Crohn’s disease: 3 year data from CHARM. Poster 8 presented at the Fourth Congress of the European Crohn’s Colitis Organisation 2009.
  17. Schwartz DA, Colombel J-F, Panaccione R, Feagan BG, Kamm MA, Chen N, Chao J, Mulani P: Sustainability of adalimumab in improving the quality of life of patients with fistulizing Crohn’s disease: 3 year data from CHARM. Poster 6 presented at the Fourth Congress of the European Crohn’s Colitis Organisation 2009.
  18. Sandborn WJ, Feagan BG, Stoinov S, Honiball PJ, Rutgeerts P, Mason D, Bloomfield R, Schreiber S for the PRECISE 1 Study Investigators: Certolizumab pegol for the treatment of Crohn’s disease. N Engl J Med 2007, 357, 228–238.
  19. Schreiber S, Karig-Kareemi M, Lawrance IC,Thomson OO, Hanauer SB, McColm J, Bloomfield R, Sandborn WJ: Maintenance therapy with certolizumab pegol for Crohn’s disease. N Engl J Med 2007, 357, 239–250.
  20. Peyrin-Biroulet L, Deltenre P, de Suray N, Branche J, Sandborn WJ, Colombel J-F: Efficacy and safety of tumor necrosis factor antagonists in Crohn’s disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol 2008, 6, 644–653.
  21. Baert F, Caprilli R, Angelucci E: Medical therapy for Crohn’s disease: top-down or step-up? Dig Dis 2007, 25, 260–266.
  22. Rutgeerts P, Vermeire S, Van Assche G: Biological therapies for inflammatory bowel disease. Gastroenterology 2009, 136, 1182–1197.
  23. Travis SPL, Stange EF, Lemann M, Öresland T, Chowers Y, Forbes A, D’Haens G, Kitis G, Cortot A, Prantera C, Marteau P, Colombel J-F, Gionchetti P, Bouhnik Y, Tiret E, Kroesen J, Starlinger M, Mortensen NJ for the European Crohn’s and Colitis Organisation (ECCO): European evidence based consensus on the diagnosis and management of Crohn’s disease: current management. Gut 2006, 55 (Suppl. I): i16–i35.
  24. Van Assche G, Dignass A, Panes J, Beaugerie L, Karagiannis J, Allez M, Ochsenkühn T, Orchard T, Rogler G, Louis E, Kupcinskas L, Mantzaris G, Travis S, Stange E for the European Crohn’s and Colitis Organisation (ECCO): The second European evidence-based consensus on the diagnosis and management of Crohn’s disease: Definitions and diagnosis J Crohn’s Colitis 2010, 4, 7–27.
  25. Travis SPL, Stange EF, Lemann M, Øresland T, Bemelman WA, Chowers Y, Colombel JF, D`Haens G, Ghosh S, Marteau P, Kruis W, Mortensen NJMcC, Pennickx F, Gassul M for the European Crohn’s and Colitis Organization (ECCO): European evidence based consensus on the management of ulcerative colitis: current management. J Crohn’s Colitis 2008, 2, 24–62.
  26. Lichtenstein GR, Hanauer SB, Sandborn WJ and The Practice Parameters Committee of The American College of Gastroenterology: Management of Crohn’s disease in adults. Am. J. Gastroenterol. advance online publication, 6 January 2009, doi: 10.1038/ajg.2008.168
  27. Bartnik W: Wytyczne postępowania w nieswoistych zapaleniach jelit. Gastroenterol Pol 2007, 14, supl. 1, 3–13.
  28. Hoentjen F, van Bodegraven AA: Safety of anti-tumor necrosis factor therapy in inflammatory bowel disease. World J Gastroenterol 2009, 15, 2067–2073.
  29. Blonski W, Lichtenstein GR: Safety of biologics in inflammatory bowel disease. Curr Treat Options Gastroenterol 2006, 221–233.
  30. Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Chen DM, Pritchard ML, Sandborn WJ: Serious infections and mortality in association with therapies for Crohn’s disease: TREAT Registry. Clin Gastroenterol Hepatol 2006, 4, 621–630.
  31. Lichtenstein GR, Diamond RH, Wagner CL, Fasanmade AA, Olson AD, Marano CW, Johanns J, Lang Y, Sandborn WJ: Benefits and risks of immunomodulators and maintenance infliximab for IBD: subgroup analyses across four randomized trials. Aliment Pharmacol Ther 10.1111/j.1365-2036.2009.04027
  32. Rahier JR et al.: European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infection in inflammatory bowel disease. J Crohn’s Colitis 2009. doi: 10.1016/j.crohn’s. 2009.02.010.
  33. Siegel CA, Marden SM, Persing SM, Larson RJ, Sands BE: Risk of lymphoma associated with combination anti-TNF and immunomodulator therapy for the treatment of Crohn’s disease: a meta-analysis. Clin Gastroenterol Hepatol 2009, doi;10.1016/j.cgh.2009.01.004.
  34. Colombel JF, Rutgeerts P, Reinisch W, Mantzaris GJ, Rachmilewitz D, Lichtiger S, D’Haens G, Woude CJ, Diamond RH, Broussard D, Hegedus R, Sandborn WJ: SONIC: a randomized, double blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn’s disease naïve to immunomodulators and biologic therapy. Gut 2008, 57. Suppl II:A1.
  35. Yun L, Hanauer S: Selecting appropriate anti-TNF agents in inflammatory bowel disease. Expert Rev Gastroenterol Hepatol 2009, 3, 235–248.
© Wroclaw Medical University